Tech Company Financing Transactions
Aadi Bioscience Funding Round
On 5/9/2017, Aadi Bioscience landed $23 million in Series A funding from Hermed Capital, Celgene and Decheng Capital.
Transaction Overview
Company Name
Announced On
5/9/2017
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Series A
Investors
Hermed Capital (Lead Investor) (Jerry Xiao)
Vivo Capital (Mahendra Shah)
Proceeds Purpose
The company will use the capital to drive the clinical programs for ABI-009, its targeted albumin-bound mTOR inhibitor.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
17383 Sunset Blvd. A250
Pacific Palisades, CA 90272
USA
Pacific Palisades, CA 90272
USA
Phone
Undisclosed
Website
Email Address
Overview
Aadi Bioscience is a clinical stage biopharmaceutical company developing the a potentially best-in-class mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Neil Desai
VP - Operations
Berta Grigorian
VP - Regulatory Affairs
Mitchall Clark
Browse more venture capital transactions:
Prev: 5/9/2017: SiFive venture capital transaction
Next: 5/9/2017: Kobalt venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs